 respons treatment leukocyte-deriv immunomodul immunocompromis patient aids-rel complex multicent double-blind placebo-control trial object cours therapi leukocyte-deriv immunomodul diseas progress patient aids-rel complex design double-blind trial set academic- community-bas clinic patient patient hiv intervent placebo week dose main result forty-eight patient placebo patient experienc advers event aids-defin opportunist infect neoplasm syndrom hiv-associ encephalopathi peripher sensori neuropathi intention-to-treat analysi kaplan-mei event probabl placebo group group cox proport hazard model rel risk patient placebo patient CI frequenc symptom baselin patient placebo mean decreas cell baselin cells/l placebo group cells/l patient patient trend increas patient size rate delay hypersensit respons placebo group conclus patient aids-rel complex advers event constitut symptom treatment loss cell size rate delay hypersensit like effect immun system toxic administr